Vaxart : Hold the Needles and the Ice – World Vaccine Congress 2021 Dr Sean Tucker

M a y 2 0 2 1	Vaxart's Oral Vaccine Candidate for
	Prevention of Covid-19

Hold the Needles and the Ice

Dr. Sean Tucker

Chief Scientific Officer

U N L O C K I N G T H E F U L L P O T E N T I A L O F O R A L V A C C I N E S

Forward-Looking Statement

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "believe," "could," "potential," "expect," "will" and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates; expected clinical results and trial data (including plans with respect to the proposed COVID-19 vaccine program); Vaxart's intention to continue its efforts to advance its oral tablet seasonal flu vaccine; Vaxart's expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV, as well as coronaviruses such as SARS, MERS and COVID-19; and Vaxart's expectations with regard to the vaccination market. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart's product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners control, including the recent outbreak of COVID-19; that Vaxart or its partners may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart's capital resources may be inadequate; Vaxart's ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.

| 2

Proprietary Oral Vaccine Platform : Vaccine Tablets

Intestinal Delivery + Targeted Immune Activation

COVID-19

ANTIGEN Norovirus

(Disease-Specific)Influenza

Ad5TLR3

DELIVERYADJUVANT

Platform: Room-temperature (25⁰C)

stable

enteric-coated tablets

("Vector-Based"(Immune

Backbone)Stimulator)

VAASTTM: Vector-Adjuvant-Antigen Standardized Technology

Manufacturing	Adjuvant & Antigen are Co-expressed:	Patents with Broad Composition of
Standardized	Potential Safety, Efficacy Benefits	Matter and Method Claims

| 3

COVID Vaccines - Where are we now?

• Vaccine developers have made advanced candidates at incredible speed
• Several needle-based vaccines have completed Phase 3
• • Expression of the S protein in people leads to substantial protection (symptomatic illness) against matched strains (Moderna, Pfizer, Astrazeneca, Janssen)
  • S Protein vaccine also protective (Novavax)
  • Drop-offin efficacy noted when the vaccine strain doesn't match the circulating strain
• Roll out >3M vaccinations a day in the US under EUA
• Coronavirus S mutations are showing up without vaccine selective pressure, including mutations in the RDB
• Discussion about building new vaccine strains that match the new coronavirus mutants

| 4

COVID-19 Vaccine Development and Distribution Efforts are Being Outpaced by Rapidly Emergent Strains

Rapid Emergence of

new SARS-CoV-2 strains

South African

strain

Vaccine

Development

Distribution & Administration

• New mutations are starting to accumulate in the S1/RBD domain, where neutralizing antibodies generated by current vaccines bind

?

• We are currently chasing the virus with vaccines like a hamster on a wheel

Current vaccine strain	Future SARS-CoV-2
	variants

| 5